Efficacy of low -frequency repetitive transcranial magnetic stimulation and setraline in treating Parkinson's ;disease patients with depression / 中国基层医药

Objective To explore the efficacy of low -frequency repetitive transcranial magnetic stimulation (rTMS)and setraline in treating Parkinson's disease patients with depression.Methods 80 cases of Parkinson's dis-ease with depression were randomly divided into the study group(administered with rTMS and setraline)and the con-trol group(administered only with setraline)according to random number table,40 cases in each group.Hamilt De-pression Rating Scale(HAMD),Unified Parkinson's Disease Rating Scale(UPDRS)and Treatment Emergent Symp-toms Scale(TESS)were assessed before treatment and 1,2,4 weeks after treatment.Results The scores of HAMD and UPDRS in the study group were lower than those in the control group[the score of HAMD at 2nd week in the study group was (18.44 ±5.56 )points,the score of HAMD at 4th week in the study group was (10.51 ± 4.27)points,the score of HAMD at 2nd week in the control group was (21.23 ±5.18)points,the score of HAMD at 4th week in the control group was (14.05 ±4.10)points,t2w =-2.322,t4w =-3.782,all P <0.05],and the score of UPDRS at 2nd week in the study group was (30.14 ±4.92)points,the score of HAMD at 4th week in the study group was (28.39 ±3.38)points,the score of UPDRS at 2nd week in the control group was (33.74 ±4.87)points, the score of HAMD at 4th week in the control group was (31.09 ±3.94)points (t2w =-3.289,t4w =-3.290,all P <0.05),while the effective rate of the study group(77.5%)was significantly higher than that in the control group (45.0%)(χ2 =4.450,P <0.05 ).Conclusion The efficacy of rTMS combined with setraline for Parkinson 's disease with depression is superior to that of using setraline alone.

Self Therapy with Sertraline as Needed Basis in Treatment of Premature Ejaculation: Short Term Follow-up Results / 대한비뇨기과학회지

PURPOSE: Pharmacotherapy using selective serotonin reuptake inhibitors(SSRls) for men with primary premature ejaculation(PE) is promising. Specially, a strategy taking a pill "as needed" may offer an attractive option. To investigate the possibility of self therapy, patients treated for PE with sertraline "as needed" basis were evaluated. MATERIALS AND METHODS: Since 1996 we have treated 24 males with sertraline "as needed" basis for primary PE. We chose sertraline among SSRIs because alarge dose need not to be divided and peak plasma levels occurring 4-8 hours after oral administration makes 5 p.m. suitable for the time of administration. Five p.m. is the time the ordinary men usually fix their evening schedule including intercourses. Each patient was started on 50mg qd for 2 weeks and then the dose was adjusted to 50 or 100mg only on the day of intercourse. RESULTS: After 6 weeks, 18 men continued to take medication and 6 had dropped out. Of 18 men, mean ejaculation latency were 23 +/-19sec before treatment, 5.9 +/-4.2min after 2wks 50mg qd, 5.1 +/-3.8min after 2wks 50/100mg pm and 4.5 +/-2.7min after 4wks 50/100mg prn and mean sexual satisfaction scores ('5"=extremely satisfied, "0"=extremely unsatisfied) of men were 0.8 +/-0.8 before treatment, 3.8 +/-1.2 after 2wks 50mg qd, 3.4 +/-1.0 after 2wks 50/100mg pm and 3.2 +/-0.7 after 4wks 50/100mg pm. And mean sexual satisfaction scores of partners were 1.1 +/-0.7 before treatment, 3.2 +/-1.6 after 2wks 50mg qd,3.1 +/-1.4 after 2wks 50/100mg pm and 3.3 +/-1.2 after 4wks 50/100mg pm. Side effects were intermittent excessive delay in 1 patient, fatigue in 2 patients, numbness in 1 patient. CONCLUSIONS: If our results were supported by additional clinical long term study, self therapy with sertraline given pm at 5 pm in treatment of PE could be as attractive as self injection therapy in the treatment of erectile dysfunction.

The Therapeutic Effect of Sertraline in Treatment-resistant Schizophrenics / 대한정신약물학회지

OBJECT: This study was undertaken to know whether there is any therapeutic effecets of sertraline in treatment-resistant schizophrenics. METHOD: Seventy seven treatment-resistant schizophrenic patients, to whom the same antipsychotics as usual were administered, were randomly assigned to two groups; to the experimental group, sertraline was and to the controlled group, placebo was administered adjuntively for 6weeks in single blind design. We assessed psychopathology by BPRS, PANSS, YBOCS, HRSD, and SCL-90-R. RESULTS: BPRS, positive scale of PANSS, and HRSD were significantly decreased in experimental group and statistically siginificant differences between the experimental group and placebo group. Negative scale of PANSS and YBOCS were significantly decresed in experimental group but no statistically significant differences between the experimental group and placebo group. The therapeutic effect of sertraline was occurred within 3rd weeks. CONCLUSION: We suggested that sertraline may be useful in the treatment of schizophrenic symtom in treatment-resistent schizophrenia, especially in positive and depressive symptoms.